Mean improvements in papilledema grade ( acetazolamide : -1.31 , from 2.76 to 1.45 ; placebo : -0.61 , from 2.76 to 2.15 ; treatment effect , -0.70 ; 95 % CI , -0.99 to -0.41 ; P < .001 ) and vision-related quality of life as measured by the National Eye Institute VFQ-25 ( acetazolamide : 8.33 , from 82.97 to 91.30 ; placebo : 1.98 , from 82.97 to 84.95 ; treatment effect , 6.35 ; 95 % CI , 2.22 to 10.47 ; P = .003 ) and its 10-item neuro-ophthalmic supplement ( acetazolamide : 9.82 , from 75.45 to 85.27 ; placebo : 1.59 , from 75.45 to 77.04 ; treatment effect , 8.23 ; 95 % CI , 3.89 to 12.56 ; P < .001 ) were also observed with acetazolamide .